Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2021-10-28 Annual Report
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
2021 Annual Report 60 pages 3.7MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report 2021' and contains detailed sections typical of an annual report, including an Operations Report, Intellectual Property Report, Directors' Report, Corporate Governance, Auditor Independence Declaration, Consolidated Financial Statements, Notes to Financial Statements, Directors' Declaration, Independent Auditor's Report, Shareholder Information, and Corporate Information. The content includes comprehensive company activities, clinical development updates, regulatory interactions, and financial data. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2021-10-28 English
Trading Halt 2 pages 239.7KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited requesting a trading halt on its securities pending the release of an announcement related to the European Medicines Agency Paediatric Committee Opinion. The text is short (2386 characters) and focuses solely on the trading halt request, with no financial data, report content, or detailed disclosures. It is not a financial report, earnings release, or management discussion. It is an operational market notice about trading status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-10-27 English
Initial Director's Interest Notice 2 pages 243.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options, and notes the date of appointment. The content is focused on disclosure of a director's personal share transactions and interests, which aligns with insider trading or director dealings. The document length is short (2514 characters) and it is a formal notice of director's interests rather than a financial report or other type of filing. Therefore, the document fits the category of Director's Dealing (DIRS).
2021-10-07 English
Antisense Therapeutics appoints new Non-Executive Director 2 pages 104.2KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 October 2021 regarding the appointment of a new Non-Executive Director to the Board of Antisense Therapeutics Limited. It details the new appointment, the retiring director, and the strategic rationale behind the board change. There is no financial data, no mention of a report being attached or published, and no regulatory certification or voting results. The content focuses solely on management/board changes. Therefore, the document fits the category of Board/Management Information (MANG). The document length (8527 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2021-10-03 English
Positive feedback received on Paediatric Investigation Plan 2 pages 152.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 September 2021 from Antisense Therapeutics Limited. It discusses receiving positive feedback on a Paediatric Investigation Plan (PIP) from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA). The announcement details the status of the PIP, the appointment of a Clinical Research Organisation, and preparations for a Phase IIb clinical trial. There are no financial statements, earnings data, or detailed financial analysis present. The document is a regulatory update about clinical development progress and regulatory feedback rather than a financial report or management discussion. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial planning and regulatory feedback without fitting other specific categories like earnings release, capital update, or management report.
2021-09-29 English
New data supports ATL1102s broader clinical potential 4 pages 298.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 24 September 2021 from Antisense Therapeutics Limited. It discusses detailed clinical trial results from a Phase II study of ATL1102 in non-ambulant Duchenne muscular dystrophy (DMD) patients, including statistically significant protein modulation data and biological implications. The text includes scientific data, references to clinical trial phases, and detailed analysis of the drug's effects on disease modifiers. It also mentions a provisional patent application related to the new data. The document is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a detailed announcement of clinical trial results and scientific findings relevant to investors and the market. Given the nature of the content—detailed clinical trial results and scientific data presented as an official company announcement—the most appropriate classification is Capital/Financing Update (CAP), as it relates to development progress and potential commercial implications of the drug ATL1102, which is material information for investors and capital markets. The document length (over 14,000 characters) and detailed content support this classification rather than a brief report publication announcement or regulatory filing.
2021-09-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.